Paper41301604
Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae.
Keck JM and 4 others. Antibiotics (Basel), 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae. Papers, record 41301604. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41301604
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40812339 | NDM-driven cefiderocol resistance: effect and therapeutic considerations. | Lancet Infect Dis | 2025 | https://conductscience.org/library/papers/40812339 | PubMed |
| 2 | 39073671 | Failure of ceftazidime/avibactam experimental therapy in the treatment of Klebsiella pneumoniae ST11 co-producing NDM-1 and OXA-48 carbapenemases infection. | Eur J Clin Microbiol Infect Dis | 2024 | https://conductscience.org/library/papers/39073671 | PubMed |
| 3 | 35992985 | A Multi-Disciplinary Approach for the Management of Prosthetic Joint Infections: An Australian Perspective. | Malays Orthop J | 2022 | https://conductscience.org/library/papers/35992985 | PubMed |
| 4 | 39389071 | Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. | Lancet Infect Dis | 2025 | https://conductscience.org/library/papers/39389071 | PubMed |
| 5 | 36225496 | A Case of New Delhi Metallo-β-Lactamases (NDM) Citrobacter sedlakii Osteomyelitis Successfully Treated With Ceftazidime-Avibactam and Aztreonam. | Cureus | 2022 | https://conductscience.org/library/papers/36225496 | PubMed |
| 6 | 39727974 | Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/39727974 | PubMed |
| 7 | 30150464 | Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/30150464 | PubMed |
| 8 | 27353166 | In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. | J Antibiot (Tokyo) | 2016 | https://conductscience.org/library/papers/27353166 | PubMed |
| 9 | 39617206 | Emergence of cefiderocol resistance during therapy in NDM-5-producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations. | Int J Infect Dis | 2025 | https://conductscience.org/library/papers/39617206 | PubMed |
| 10 | 39766611 | Characterization of Metallo β-Lactamase Producing Enterobacterales Isolates with Susceptibility to the Aztreonam/Avibactam Combination. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39766611 | PubMed |
| 11 | 41028326 | In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii. | Sci Rep | 2025 | https://conductscience.org/library/papers/41028326 | PubMed |
| 12 | 36875177 | In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer. | JAC Antimicrob Resist | 2023 | https://conductscience.org/library/papers/36875177 | PubMed |
| 13 | 39174036 | Clinic of Hope: bridging infectious disease and orthopaedic surgery in prosthetic joint infection management. | BMJ Open Qual | 2024 | https://conductscience.org/library/papers/39174036 | PubMed |
| 14 | 40005507 | Antimicrobial Treatment Options for Multidrug Resistant Gram-Negative Pathogens in Bone and Joint Infections. | Pathogens | 2025 | https://conductscience.org/library/papers/40005507 | PubMed |
| 15 | 34950677 | Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms. | Front Med (Lausanne) | 2021 | https://conductscience.org/library/papers/34950677 | PubMed |
| 16 | 40859163 | In vitro activity of Eravacycline against carbapenem-resistant gram-negative bacilli and associated risk factors for non-susceptible infections from a tertiary hospital in fujian, China from 2021 to 2024. | BMC Microbiol | 2025 | https://conductscience.org/library/papers/40859163 | PubMed |
| 17 | 40053286 | Clinical outcomes of patients hospitalized in internal medicine wards adequately treated for bloodstream infections caused by NDM-producing Klebsiella pneumoniae. Results from a real-life retrospective multi-center study in an endemic area. | Infection | 2025 | https://conductscience.org/library/papers/40053286 | PubMed |
| 18 | 40902970 | Prevalence, Clinical Characteristics, and Mortality Impact of Metallo-β-Lactamase-Producing Enterobacter Cloacae Complex Infections: A Retrospective Cohort Study. | J Glob Antimicrob Resist | 2025 | https://conductscience.org/library/papers/40902970 | PubMed |
| 19 | 39299261 | Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. | Lancet | 2024 | https://conductscience.org/library/papers/39299261 | PubMed |
| 20 | 40521716 | Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023). | J Antimicrob Chemother | 2025 | https://conductscience.org/library/papers/40521716 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42876900 | The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens. | JAC Antimicrob Resist | 2026 | https://conductscience.org/library/papers/42876900 | PubMed |
| 42192725 | Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42192725 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41301604
GET https://conductscience.org/api/papers/v1/41301604/references?page=2